TRTH-03. CYTO-MITO™ - A NOVEL CLASS OF DUAL-ACTING HSP90 INHIBITORS FOR THE TREATMENT OF GLIOBLASTOMA

Glioblastoma (GBM) is a highly invasive and aggressive primary brain tumor and is considered one of the deadliest forms of cancer. Despite aggressive therapies, half of GBM patients die within 15 months after diagnosis and only 2% survive more than 5 years. Therefore, effective treatments for GBM re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Natala, Srinivasa Reddy, Siddique, Shyama, Carney, David, Mladek, Ann, Stebbins, Jeffrey, Yang, Li, Lee, Pooi San, Brimberry, Daniel, Ardecky, Robert, Teriete, Peter, Rubenstein, Allan, Sarkaria, Jann, Cosford, Nicholas, Prasad, Sridhar
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475182/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.215
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados